Sorafenib is a Raf1 / Mek / Erk kinase inhibitor used to treat hepatocellular carcinoma (Adjibade et al., 2015), thyroid carcinoma (Lin et al., 2021), and renal carcinoma (Chen W. et al., 2018). This evidence concerns the gene MAP2K7 and thyroid gland carcinoma.